Form 4: Terns Pharma CEO Burroughs Exercises Options, Sells Shares

Terns Pharmaceuticals CEO Amy L. Burroughs exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• Amy L. Burroughs, Chief Executive Officer and Director of Terns Pharmaceuticals, Inc., executed transactions involving the company's common stock on March 16, 2026.
• Burroughs acquired 14,583 shares of common stock by exercising stock options at a price of $4.64 per share.
• Following the option exercise, Burroughs sold a total of 14,583 shares of common stock in two separate transactions.
• The first sale involved 11,813 shares at a weighted average price of $46.5657 per share, with prices ranging from $46.01 to $47.005.
• The second sale involved 2,770 shares at a weighted average price of $47.3024 per share, with prices ranging from $47.01 to $47.91.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2025.
• After these transactions, Burroughs directly owns 288,976 shares of common stock and indirectly owns 8,319 shares through the Amy L Burroughs 2017 Trust.
• Burroughs also holds 955,534 unexercised stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The executive is realizing value from long-held options, which is a normal part of compensation, and the pre-planned nature reduces any negative signaling.

Positives

• The executive realized significant value by exercising stock options at $4.64 per share and selling the acquired shares at weighted average prices of $46.5657 and $47.3024, indicating substantial paper gains.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a disciplined approach to managing equity compensation and reduces concerns about opportunistic timing.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, reduces their direct ownership stake in the company, which some investors might interpret as a slight reduction in insider conviction.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are common for executives managing their equity compensation and personal finances. While sales can sometimes raise questions, a 10b5-1 plan indicates the decision to sell was made in advance, mitigating concerns about opportunistic timing based on non-public information. This is a routine event in the lifecycle of executive compensation.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of executives exercising stock options and subsequently selling shares is a standard component of executive compensation realization across various industries, particularly in biotechnology where equity forms a significant portion of total compensation.
• The substantial difference between the exercise price ($4.64) and the sale prices (mid-$40s) reflects significant value creation for the executive, aligning with typical incentive structures designed to reward long-term stock price appreciation.
• No specific comparable companies, projects, or results are detailed in this Form 4 to allow for a direct comparison of operational or financial performance against industry benchmarks.

Related Party Transactions

• Amy L. Burroughs beneficially owns 8,319 shares indirectly through the Amy L Burroughs 2017 Trust, which is a standard disclosure for executive holdings.

Stakeholder Impact

• Shareholders: The sale of shares by a CEO, even if pre-planned, slightly reduces insider ownership, which some shareholders might view with caution. However, the significant profit realized by the executive could be seen as a positive indicator of company value growth.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The remaining 955,534 stock options held by Amy L. Burroughs will continue to vest according to their schedule, with 25% vesting on the first anniversary from January 1, 2025, and 1/48th of the total shares vesting monthly thereafter until fully vested on the fourth anniversary.

Key Dates

Recommendation

The transactions are routine insider sales executed under a pre-arranged 10b5-1 plan, indicating no new material information or change in the executive's long-term outlook on the company. While the executive is realizing significant gains, this is a standard part of equity compensation management and does not provide a strong signal for immediate buying or selling based solely on this filing.

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Trading, Stock Options, CEO, Amy L. Burroughs, 10b5-1 Plan, Equity Compensation, Share Sale